ReviewPediatric nephrology (Berlin, Germany)2016
Platelet abnormalities in nephrotic syndrome.
Review in Pediatric nephrology (Berlin, Germany), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 42 citations in OpenAlex.
- Article
- Article
- Venous Thromboembolism Prevention in Nephrotic Syndrome: The Role of Aspirin, Vitamin K Antagonists, and Direct Oral Anticoagulants.Kidney international reports · 2025Review
- Nomogram for thromboembolic events in primary membranous nephropathy associated with PLA2R antibody.Scientific reports · 2025Article
- Aortic valve thrombosis in nephrotic syndrome: a case report.Journal of nephrology · 2025Article
- Modeling a biofluid-derived extracellular vesicle surface signature to differentiate pediatric idiopathic nephrotic syndrome clinical subgroups.Scientific reports · 2024Article
- Association of elevated circulating monocyte-platelet aggregates with hypercoagulability in patients with nephrotic syndrome.Thrombosis journal · 2024Article
- Research progress of nephrotic syndrome accompanied by thromboembolism.International urology and nephrology · 2023Review
- Venous Thromboembolism in Kidney Diseases and Genetic Predisposition.Kidney diseases (Basel, Switzerland) · 2022Review
- Nephrotic Syndrome Complications - New and Old. Part 1.Maedica · 2022Article
- Role of Arachidonic Acid and Its Metabolites in the Biological and Clinical Manifestations of Idiopathic Nephrotic Syndrome.International journal of molecular sciences · 2021Review
- Extreme thrombocytosis is associated with critical illness and young age, but not increased thrombotic risk, in hospitalized pediatric patients.Journal of thrombosis and haemostasis : JTH · 2020Article
- Nephrotic syndrome-associated hypercoagulopathy is alleviated by both pioglitazone and glucocorticoid which target two different nuclear receptors.Physiological reports · 2020Article
- Augmentation index, a predictor of cardiovascular events, is increased in children and adolescents with primary nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2020Observational
- Management of anticoagulation and antiplatelet therapy in patients with primary membranous nephropathy.BMC nephrology · 2019Review
- Article
- Association of infections and venous thromboembolism in hospitalized children with nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2019Article
- Identification of novel molecular signatures of IgA nephropathy through an integrative -omics analysis.Scientific reports · 2017Article
- Pituitary adenylate cyclase-activating polypeptide (PACAP) in zebrafish models of nephrotic syndrome.PloS one · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nephrotic syndrome (NS) is a common kidney disease associated with a significantly increased risk of thrombotic events. Alterations in plasma levels of pro- and anti-coagulant factors are involved in the pathophysiology of venous thrombosis in NS. However, the fact that the risk of both venous and arterial thrombosis is elevated in NS points to an additional role for blood platelets. Increased platelet counts and platelet hyperactivity have been observed in nephrotic children. Platelet hyperaggregability, increased release of active substances, and elevated surface expression of activation-dependent platelet markers have been documented. The mechanisms underlying those platelet alterations are multifactorial and are probably due to changes in plasma levels of platelet-interfering proteins and lipid changes, as a consequence of nephrosis. The causal relationship between platelet alterations seen in NS and the occurrence of thromboembolic phenomena remains unclear. Moreover, the efficiency of prophylactic treatment using antiplatelet agents for the prevention of thrombotic complications in nephrotic patients is also unknown. Thus, antiplatelet medication is currently not generally recommended for routine prophylactic therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.